Whan In Pharm Co.,Ltd. (016580.KS)
KRW 11930.0
(-0.33%)
KRW 11930.0
(-0.33%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 401.22 Billion KRW | 8.62% |
| 2022 | 369.37 Billion KRW | 4.58% |
| 2021 | 353.18 Billion KRW | 7.17% |
| 2020 | 329.55 Billion KRW | 8.09% |
| 2019 | 304.88 Billion KRW | 5.98% |
| 2018 | 287.68 Billion KRW | 4.68% |
| 2017 | 274.83 Billion KRW | 12.9% |
| 2016 | 243.44 Billion KRW | 3.57% |
| 2015 | 235.05 Billion KRW | 7.9% |
| 2014 | 217.84 Billion KRW | 12.81% |
| 2013 | 193.1 Billion KRW | 6.43% |
| 2012 | 181.42 Billion KRW | 9.22% |
| 2011 | 166.1 Billion KRW | 21.28% |
| 2010 | 136.96 Billion KRW | 15.15% |
| 2009 | 118.94 Billion KRW | 10.57% |
| 2008 | 107.57 Billion KRW | 1.26% |
| 2007 | 106.23 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 421.03 Billion KRW | 1.33% |
| 2024 Q1 | 415.52 Billion KRW | 3.56% |
| 2023 FY | 401.22 Billion KRW | 8.62% |
| 2023 Q4 | 401.22 Billion KRW | 2.69% |
| 2023 Q3 | 390.69 Billion KRW | 1.11% |
| 2023 Q2 | 386.39 Billion KRW | 1.06% |
| 2023 Q1 | 382.34 Billion KRW | 3.51% |
| 2022 Q3 | 358.6 Billion KRW | 2.27% |
| 2022 Q2 | 350.63 Billion KRW | -1.25% |
| 2022 FY | 369.37 Billion KRW | 4.58% |
| 2022 Q4 | 369.37 Billion KRW | 3.0% |
| 2022 Q1 | 355.08 Billion KRW | 0.54% |
| 2021 Q3 | 344.8 Billion KRW | 1.63% |
| 2021 FY | 353.18 Billion KRW | 7.17% |
| 2021 Q1 | 334.31 Billion KRW | 1.44% |
| 2021 Q2 | 339.28 Billion KRW | 1.49% |
| 2021 Q4 | 353.18 Billion KRW | 2.43% |
| 2020 FY | 329.55 Billion KRW | 8.09% |
| 2020 Q1 | 306.9 Billion KRW | 0.66% |
| 2020 Q2 | 309.66 Billion KRW | 0.9% |
| 2020 Q3 | 321.77 Billion KRW | 3.91% |
| 2020 Q4 | 329.55 Billion KRW | 2.42% |
| 2019 Q1 | 300.27 Billion KRW | 4.37% |
| 2019 FY | 304.88 Billion KRW | 5.98% |
| 2019 Q4 | 304.88 Billion KRW | 1.77% |
| 2019 Q3 | 299.58 Billion KRW | 1.57% |
| 2019 Q2 | 294.95 Billion KRW | -1.77% |
| 2018 Q2 | 276.42 Billion KRW | -2.02% |
| 2018 FY | 287.68 Billion KRW | 4.68% |
| 2018 Q4 | 287.68 Billion KRW | 0.71% |
| 2018 Q3 | 285.64 Billion KRW | 3.34% |
| 2018 Q1 | 282.12 Billion KRW | 2.65% |
| 2017 FY | 274.83 Billion KRW | 12.9% |
| 2017 Q3 | 260.82 Billion KRW | 2.06% |
| 2017 Q4 | 274.83 Billion KRW | 5.37% |
| 2017 Q1 | 249.05 Billion KRW | 2.3% |
| 2017 Q2 | 255.55 Billion KRW | 2.61% |
| 2016 Q1 | 239.45 Billion KRW | 1.88% |
| 2016 Q3 | 239.23 Billion KRW | -0.7% |
| 2016 Q4 | 243.44 Billion KRW | 1.76% |
| 2016 FY | 243.44 Billion KRW | 3.57% |
| 2016 Q2 | 240.91 Billion KRW | 0.61% |
| 2015 Q4 | 235.05 Billion KRW | 2.95% |
| 2015 Q1 | 223.21 Billion KRW | 2.47% |
| 2015 Q3 | 228.3 Billion KRW | 1.12% |
| 2015 Q2 | 225.77 Billion KRW | 1.15% |
| 2015 FY | 235.05 Billion KRW | 7.9% |
| 2014 Q4 | 217.84 Billion KRW | 6.95% |
| 2014 FY | 217.84 Billion KRW | 12.81% |
| 2014 Q3 | 203.69 Billion KRW | 2.56% |
| 2014 Q2 | 198.61 Billion KRW | 0.6% |
| 2014 Q1 | 197.42 Billion KRW | 2.24% |
| 2013 Q4 | 193.1 Billion KRW | 4.01% |
| 2013 FY | 193.1 Billion KRW | 6.43% |
| 2013 Q1 | 183.95 Billion KRW | 1.39% |
| 2013 Q2 | 182.02 Billion KRW | -1.05% |
| 2013 Q3 | 185.65 Billion KRW | 1.99% |
| 2012 Q1 | 170.07 Billion KRW | 2.39% |
| 2012 Q4 | 181.42 Billion KRW | 3.24% |
| 2012 Q2 | 172.84 Billion KRW | 1.63% |
| 2012 FY | 181.42 Billion KRW | 9.22% |
| 2012 Q3 | 175.73 Billion KRW | 1.67% |
| 2011 Q2 | 162.22 Billion KRW | 3.2% |
| 2011 Q1 | 157.19 Billion KRW | 14.78% |
| 2011 Q3 | 163.1 Billion KRW | 0.54% |
| 2011 FY | 166.1 Billion KRW | 21.28% |
| 2011 Q4 | 166.1 Billion KRW | 1.84% |
| 2010 Q3 | 131.35 Billion KRW | 4.89% |
| 2010 Q2 | 125.23 Billion KRW | 1.69% |
| 2010 Q4 | 136.96 Billion KRW | 4.27% |
| 2010 Q1 | 123.15 Billion KRW | 3.53% |
| 2010 FY | 136.96 Billion KRW | 15.15% |
| 2009 Q3 | 119.46 Billion KRW | 3.56% |
| 2009 FY | 118.94 Billion KRW | 10.57% |
| 2009 Q2 | 115.35 Billion KRW | 2.19% |
| 2009 Q1 | 112.88 Billion KRW | 4.93% |
| 2009 Q4 | 118.94 Billion KRW | -0.43% |
| 2008 Q2 | 109.03 Billion KRW | -0.67% |
| 2008 Q3 | 109.51 Billion KRW | 0.44% |
| 2008 Q4 | 107.57 Billion KRW | -1.77% |
| 2008 FY | 107.57 Billion KRW | 1.26% |
| 2008 Q1 | 109.77 Billion KRW | 3.33% |
| 2007 Q3 | 106.6 Billion KRW | -0.68% |
| 2007 Q4 | 106.23 Billion KRW | -0.35% |
| 2007 FY | 106.23 Billion KRW | 0.0% |
| 2007 Q1 | 101.77 Billion KRW | 0.0% |
| 2007 Q2 | 107.33 Billion KRW | 5.46% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -102.421% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 79.499% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 54.25% |
| HANDOK Inc. | 790.33 Billion KRW | 49.234% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -135.158% |
| Yuhan Corporation | 2814.07 Billion KRW | 85.742% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 69.494% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -329.216% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 79.446% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -67.354% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 14.433% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -248.974% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -69.617% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -15.167% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -102.421% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 4.285% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 19.719% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 31.926% |
| JW Holdings Corporation | 1176.26 Billion KRW | 65.89% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 34.361% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 71.391% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 37.798% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -14.609% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -160.467% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -8.241% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 17.668% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -102.421% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 62.783% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 77.336% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 37.798% |
| Yuhan Corporation | 2814.07 Billion KRW | 85.742% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 54.406% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -77.063% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 59.624% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 37.798% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 4.447% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 14.425% |
| CKD Bio Corp. | 293.78 Billion KRW | -36.571% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 21.018% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 28.983% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -14.609% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 72.443% |
| Boryung Corporation | 922.36 Billion KRW | 56.5% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 9.32% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 14.433% |
| JW Lifescience Corporation | 255.83 Billion KRW | -56.829% |